Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

SINA, Among Billionaire Lei Zhang’s Big Purchases in Q2

Leading investment management firm Hillhouse Capital Management, founded by billionaire Lei Zhang, invests in various asset classes with a long-term time horizon. The fund uses a fundamental bottom-up approach to stock selection and focuses its investments in the consumer, tech, and healthcare industries.

As of the latest 13F reporting period, Hillhouse Capital Management held a U.S. equity portfolio with positions valued at $3.97 billion, down from $4.58 billion at the end of the March. In this article, we’ll take a look at Hillhouse Capital Management’s five biggest purchases made during second quarter.

We believe that imitating hedge funds and other large institutional investors can be helpful in identifying stocks capable of outperforming the broader market. Through extensive research that covered portfolios of several hundred large investors between 1999 and 2012, we determined that following the small-cap stocks that large money managers are collectively bullish on, can generate monthly returns nearly 1.0 percentage points above the market (see more details here).

Lei Zhang Hillhouse Capital

Clearside Biomedical Inc (NASDAQ:CLSD)

– Shares Owned by Hillhouse Capital Management (as of June 30): 600,000

– Value of Hillhouse Capital Management’s Holding (as of June 30): $4.21 million

Hillhouse Capital Management added late-stage clinical biopharmaceutical company Clearside Biomedical Inc (NASDAQ:CLSD) to its portfolio during the second quarter, buying 600,000 shares of the company worth $4.21 million on June 30. Clearside Biomedical, which began trading on the NASDAQ on June 2, reported revenue of $5,000 and a net loss of $0.62 per share for the second quarter. The company recently announced positive results from its phase-2 clinical trial for TANZANITE in Macular Edema Associated with Retinal Vein Occlusion (RVO), as patients achieved better results, while fewer of them needed additional intravitreal Eylea treatments compared to a control group. Shares of Clearside Biomedical have dipped by 2.76% since the company’s IPO. A total of eight funds in our database opened long positions in Clearside Biomedical Inc (NASDAQ:CLSD)  during the second quarter.

Follow Clearside Biomedical Inc.
Trade (CLSD) Now!

Liberty Global plc – Class A Ordinary Shares (NASDAQ:LBTYA)

– Shares Owned by Hillhouse Capital Management (as of June 30): 672,000

– Value of Hillhouse Capital Management’s Holding (as of June 30): $19.53 million

Hillhouse Capital Management added a new position in cable television and internet services company Liberty Global plc – Class A Ordinary Shares (NASDAQ:LBTYA) during the second quarter, acquiring 672,000 shares worth $19.53 million. The company appointed Charlie Bracken as its new CFO after Bernie Dvorak announced his retirement as Co-CFO. The company is also adding KPMG Partner Jason Waldron as its Chief Accounting Officer, with his tenure beginning on October 1. A total of 51 funds in our database held shares of Liberty Global plc – Class A Ordinary Shares (NASDAQ:LBTYA) at the end of June, with an aggregate value of $1.59 billion.

Follow Liberty Global Inc.
Trade (LBTY) Now!

On the next page we’ll discuss the rest of Hillhouse’s major second quarter moves, which involved RenaissanceRe Holdings, SINA Corp, and Inc.